Plantibodies

Have you tried to ask ChatGPT : What is that company I'm working for ? An amazing concise and precise result indeed! 💊💊💊 🧬 Plantibodies.tech is a biotechnology company specializing in the production of therapeutic antibodies and biologics using plants as bioreactors. The company leverages plants, which are genetically modified to produce antibodies, proteins, or other therapeutic agents that can be used to treat serious diseases such as cancer, viral infections, and inflammatory diseases. 💊 Their key innovation is transforming intravenous (IV) biologics into oral capsule formulations. This allows for the same efficacy as IV-administered treatments, but in a more convenient, oral form. The goal is to create therapies with an extended therapeutic window—meaning the treatments remain effective for longer durations while reducing side effects compared to traditional administration. ♻️ This method also offers the advantage of patent extensions for previously developed biologics. #Biotechnology #Immunotherapy #GutHealth #OralBiologics #PlantBiotechnology #ColorectalCancer #InflammatoryBowelDisease #MonoclonalAntibodies #PharmaInnovation #SustainabilityInHealth #GreenBiologics #DrugDelivery #Biopharma #HealthcareInnovation #PrecisionMedicine #TissueResidentMemoryCells #PlantMadePharmaceuticals #FutureOfMedicine #CollaborateForHealth

🚀 Revolutionizing Biologic Therapies with Plantibodies 🌱 At Plantibodies, we’re pushing the boundaries of biologics delivery by developing plant-based, colon-targeted oral therapies. Our mission? To create sustainable, patient-friendly treatments for gut-related diseases like colorectal cancer and inflammatory bowel disease (IBD), with minimal systemic toxicity and enhanced precision. 🌿 What’s new? We’ve harnessed the power of plants to produce and encapsulate biologics that target tissue-resident immune cells in the gut, offering a groundbreaking alternative to traditional IV-administered therapies. The potential is immense—from reducing toxic side effects to making cutting-edge biologics more globally accessible. 🌍 🔗 Read more about how we’re transforming biologics and shaping the future of gut disease treatment: #Biotechnology #GutHealth #OralBiologics #ColorectalCancer #IBD #PlantBased #PharmaInnovation #GreenBiologics #SustainabilityInHealth

#BIOMAN4R2 𝙎𝙐𝘾𝘾𝙀𝙎𝙎 𝙎𝙏𝙊𝙍𝙄𝙀𝙎 Discover how our Financial Support Program💰 improves patients’ quality of life! ⏩ Check out our #5 Success Story: 🏅 Plantibodies is  one of the awarded companies within the INNOVATION FINANCIAL SUPPORT category. "Plantibodies developed a drug delivery platform to administer oral biologics targeting the gastrointestinal mucosa, opening up an untapped new frontier in human medicine. By combining two critical technologies to deliver high concentrations of oral biologics in the gastrointestinal tract, Plantibodies enables high targets engagement in the gut, sparing the systemic compartment to avoid toxicities while treating GI tract diseases." “The project funded under BioMan4R2 tackled plant manufacturing process development to bioproduce monoclonal #antibodies at scale, oral drug formulation development, and assessment of biodistribution in the gastrointestinal tract. The company has shown the ability to produce and bioencapsulate monoclonal antibodies in #plantcells, and to release them to the gastrointestinal mucosa. This opens opportunities for further development of Plantibodies delivery platform and is a step forward bringing drug candidates to the clinic, for the patients.” We would like to express our gratitude to Plantibodies for their valuable testimonial. 🙏 Congratulations for your achievements! 🎉 #resilience #europeanunion #biotech #innovation #medicaldevice #EUfunding #medtech #cascadefunding Turku Science Park Ltd Council of European BioRegions - CEBR Biocat, BioRegion of Catalonia BioRegio STERN Management GmbH MedSilesia Cluster - Silesian Medical Devices Network Górnośląski Akcelerator Przedsiębiorczości Rynkowej sp. z o.o. Medicen Paris Region LifetecZONe Plantibodies

Unlocking the Future of Oral Protein Drugs with Plant-Based Bioencapsulation 🌱 Bioencapsulation is revolutionizing the way we think about the delivery of protein drugs (PDs), offering unparalleled stability and biodistribution for orally administered treatments. 🌍 Did you know? The @FDA now approves the use of plant cells for the cost-effective, large-scale production of PDs in cGMP hydroponic growth facilities. In lyophilized form, these plant cells can preserve PDs at ambient temperatures for years, ensuring they maintain their structure and efficacy. 🌿💊 But that’s not all—plant cell walls, rich in lignin and cellulose, offer robust protection in the GI tract. Human enzymes can’t break down these glycosidic bonds, ensuring that the encapsulated PDs remain intact until they reach the gut lumen, where local microbiota step in. 🌱🛡️ Our innovative approach at Plantibodies involves compressing lyophilized transgenic plant tissue into tablets, though we also explore enteric capsule drug delivery technologies (ECDDT) for additional protection. 🌾 So, what makes a plant ideal for oral therapies? Here’s our checklist:   🌿 Rapid maturation for economic viability.   🧪 Free from secondary metabolites that could interfere with the transgenic protein.   🥦 Consumable in its raw form to protect antigen integrity.   💪 High protein production capacity. At Plantibodies, our patented plant checks all the boxes. We’re currently conducting growth experiments to quantify protein production over time and fine-tune this groundbreaking platform. If you're curious to learn more about how plant cell bioencapsulation is revolutionizing the field, please read the very insightful paper by @Kwang-Chul Kwon View @Kwang-Chul Kwon profile and @Henry Daniell from the University of Pennsylvania. 📚 💡 The future of oral protein drugs is green, stable, and efficient. Together, we’re cultivating a healthier tomorrow! 🌟 #Bioencapsulation #ProteinDrugs #PlantBasedTherapies #BiotechInnovation #Plantibodies #Sustainability #Mabs #sorbonne

🔬 Current Challenges in GI Tract Immunotherapy: Invasive, Off-Target and Unsustainable 🌍 In the fight against GI tract diseases, monoclonal antibodies (mAbs) have become a cornerstone of treatment, tackling conditions from Crohn's Disease to various forms of cancer. However, these powerful biologics come with #unsustainable downsides : 💉 Invasive Administration: Currently, all approved mAb therapies for GI conditions are administered intravenously or subcutaneously. This route of administration is invasive, often leading to discomfort and requiring medical supervision. ❗️ Side Effects & Off-Target: These drugs, targeting crucial immune system components, can cause severe side effects. Off-target further complicates treatment, necessitating higher doses and more frequent administration. 💰 High Costs: Keytruda and Humira generated +40 billion in revenue, reflecting not just their effectiveness but also the steep price patients and healthcare systems must bear. 🌱 Environmental Concerns: Traditional mAb production involves CHO cells in bioreactors—a process that is not only costly but also environmentally taxing. At Plantibodies, we are pioneering a new generation of treatments - accessible, non-toxic, locally effective, and environmentally sustainable. 🌱 Our approach uses plant-based systems to produce therapeutics that are less invasive and more patient-friendly, aiming to revolutionize the treatment landscape for GI tract diseases. Let’s move toward a future where effective treatment doesn’t come at such a high cost—financially, physically, or environmentally. #biotechnology #GItract #immunotherapy #innovation #healthcare #Plantibodies #mAbs #oraladministration #biologics #Mabs #cancer #IA #sorbonne

🚀 Breaking Barriers in Oral Delivery: Revolutionizing Macromolecule Treatments with Plantibodies 🌱 📌  The struggle to achieve oral delivery of macromolecules in the lower part of the GI-tract continues, especially in targeting diseases like: ·     Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and, ulcerative colitis (UC), and, ·     Colorectal cancer (CRC) While small molecules have seen success (see previous post), the pharmaceutical industry still faces challenges in delivering larger molecules accurately and effectively. As of today, we cannot simply leverage the technology developed for small molecules to develop dosage forms for local delivery of macromolecules. There is a clear need for transformation for delivering macromolecules. We need to ensure accurate and reproducible release, however these payloads have their own special needs related to ensuring encapsulation of antibodies. If the pharmaceutical industry has succeeded to deliver small molecules orally with the Rybelsus technology, the technical hurdles to achieve accurate and reproducible colonic delivery of macromolecules are high. ❗️ Overly-complex multifunctional component dosage form design, inadequate loading, ❗️ Incompatibility between the macromolecule and the dosage form, and variability in the triggering of release in the colon, ❗️ Struggle to pass stomach conditions, ❗️ Systemic effect with strong side effects. For a deeper dive into these challenges, check out this insightful paper written by AstraZeneca R&D team. 🌱 Plantibodies Solution: Plantibodies is pioneering innovative strategies to overcome these challenges, focusing on local macromolecule delivery to treat diseases like IBD and colorectal cancer through the power of plants. 🌱 💡 Smart and simplified component dosage form design, and adequate loading,  💡 Compatibility between the macromolecule and the dosage form, and constancy in the triggering of release in the colon, 💡 Succeed to pass stomach conditions, 💡 Local effect (acting in the colonic lumen) with reduced toxicity.   #MacromoleculeDelivery #IBD #ColorectalCancer #Plantibodies #Biotech #DrugDelivery #HealthcareInnovation #OralDelivery #MolecularFarming

So proud to be part as a new member of California Life Sciences! 👋🏾

Oral delivery for biologics is a must in consideration of patients’s expectations. #biologics#mabs#betterhealth#

🚀 Revolutionizing Administration: From INJECTIONS to ORAL DELIVERY 💊 The case study of Rybelsus. An example of a biobetter drug that has transitioned from an injectable form to an oral formulation is Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying. 💉 Initially, semaglutide was available only as an injectable formulation (Ozempic), to manage blood sugar levels and promote weight loss in patients with type 2 diabetes, with a weekly administration. 💊 The development of the oral formulation, Rybelsus, marketed in 2019, represents a significant advancement, providing a non-injectable option for patients taken once daily. Benefits of the Oral Formulation: 1. Enhanced Glycemic Control: Oral semaglutide provides effective glycemic control, reducing HbA1c levels significantly more than some other oral glucose-lowering therapies. 2. Weight Reduction: Studies indicate that Rybelsus aids in weight reduction, a crucial benefit for many patients with type 2 diabetes. 3. Cardiovascular Benefits: Oral semaglutide demonstrated a favorable cardiovascular safety profile, comparable to injectable semaglutide. 4. Convenient Administration: The oral formulation allows for easier administration, improving patient adherence and comfort by eliminating the need for injections. Development and Approval: ▪ Clinical Trials: The development of Rybelsus involved demonstrating that the oral formulation of semaglutide could be absorbed effectively in the gastrointestinal tract and provide consistent blood levels to achieve the desired therapeutic effects. Trials compared the efficacy and safety of oral semaglutide with the injectable form and other diabetes medications. ▪ Regulatory Approval: Rybelsus was approved by the FDA based on positive clinical trial results, providing a new and innovative option for diabetes management. The transition from injectable Ozempic to oral Rybelsus illustrates how changing the delivery method of a medication can significantly enhance patient convenience and adherence while maintaining therapeutic efficacy. This shift exemplifies the “BioBetter” concept by offering a more patient-friendly option without compromising the effectiveness of the treatment. 🌱💡At Plantibodies, we are following this path by addressing other gastrointestinal diseases with innovative oral formulations. Hopefully, soon GI-tract diseases will no longer need to be treated with injections, making therapies more accessible and comfortable for patients and lowering the burden on the health-care system. To gain comprehensive insights into the scientific advantages of Rybelsus over Ozempic, read the instructive publication of Filip K. Knop, Andrea Battisti, and Tina Vilsbøll here: https://lnkd.in/gvMfQ5_g #mAbs #Oraldelivery #Biotechnology #MolecularFarming #Biologics #Lifesciences

🚀 Biobetters: Revolutionizing Patient Care! 🚀 The global #biobetters market is experiencing tremendous growth, projected to soar from USD 60.61 billion in 2023 to USD 138.56 billion by 2033 and an 8.62% CAGR. This surge is driven by the demand for more effective treatments with fewer side effects, especially in chronic diseases like cancer and autoimmune disorders. 🚀 The fastest growing segment for the last years has been insulin – why? Because of the breakthrough in oral delivery translating in better patient compliance. At Plantibodies, we’re seizing this opportunity by focusing on monoclonal antibody biobetters—the segment that dominated the market in 2023 with our first program on colorectal cancer. Our innovative approach uses molecular farming to develop ORAL biobetters, offering a solution that is: 💸 Cheaper 🌱 More sustainable ✅ Less toxic 🙏 Strongly demanded by patients With a unique method of production, we develop validated monoclonal antibodies in a new way to deliver enhanced therapeutic options that meet the evolving needs of patients. If you're interested in learning more about this fascinating market, please read the market study: https://lnkd.in/eFSwWcfd Join us as we lead the charge in this rapidly expanding market! #Biobetters #HealthcareInnovation #Plantibodies #Biotechnology #MolecularFarming #MonoclonalAntibodies